Hepatic effects of duloxetine-I: non-clinical and clinical trial data.
about
Safety and tolerability of duloxetine in the acute management of diabetic peripheral neuropathic pain: analysis of pooled data from three placebo-controlled clinical trials.Which adverse effects influence the dropout rate in selective serotonin reuptake inhibitor (SSRI) treatment? Results for 50,824 patientsDuloxetine-induced liver injury in patients with major depressive disorder.Hepatic outcomes among adults taking duloxetine: a retrospective cohort study in a US health care claims databaseEfficacy of Duloxetine in Patients with Chronic Pain ConditionsAnswers to the most common questions about the hepatic safety profile of duloxetine.Efficacy and safety of duloxetine 60 mg once daily in major depressive disorder: a review with expert commentaryUse of duloxetine in patients with an anxiety disorder, or with comorbid anxiety and major depressive disorder: a review of the literature.Cholestatic jaundice induced by duloxetine in a patient with major depressive disorderCost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective.Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology.Duloxetine: urinary incontinence and marketing authorization incontinence.Ammoxetine attenuates diabetic neuropathic pain through inhibiting microglial activation and neuroinflammation in the spinal cord.
P2860
Q33577285-5DD3D574-1FE7-438E-B60A-ABC2757C2ACEQ34368534-B2EF19E7-1999-4FA7-862B-8D854221C804Q35238358-EFADF798-D38B-46FD-B0A6-B254E24BB740Q35807663-164BFA86-291A-4AC2-B89A-BD7D41572867Q36141335-B614B91B-3A94-4B16-A9E5-12BC96A6341DQ37226413-FF4A01D9-B110-4C13-B03A-BB67A727A424Q37449200-36639B42-44C7-40C7-A297-7BEECF5E253EQ37733559-7D7B0E6D-1B63-4174-9CBC-208798D39BF5Q42013874-94B1072B-91E5-472C-8C6D-FA835E835944Q45347178-671ACAE4-2532-4BD4-8656-38AC7B1DD72EQ53091817-A6E8D1C3-2624-4841-A04D-49408E4BBD4DQ53761031-8488B88A-BD1E-4D48-850D-015B8622D3AEQ54976781-EE074530-5412-43B2-8B33-43BDAE8A7D3D
P2860
Hepatic effects of duloxetine-I: non-clinical and clinical trial data.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Hepatic effects of duloxetine-I: non-clinical and clinical trial data.
@ast
Hepatic effects of duloxetine-I: non-clinical and clinical trial data.
@en
type
label
Hepatic effects of duloxetine-I: non-clinical and clinical trial data.
@ast
Hepatic effects of duloxetine-I: non-clinical and clinical trial data.
@en
prefLabel
Hepatic effects of duloxetine-I: non-clinical and clinical trial data.
@ast
Hepatic effects of duloxetine-I: non-clinical and clinical trial data.
@en
P2093
P1433
P1476
Hepatic effects of duloxetine-I: non-clinical and clinical trial data.
@en
P2093
Beth Pangallo
Deborah N D'Souza
Fujun Wang
Isabelle Murray
Jack P Uetrecht
Joachim Wernicke
Judith W Henck
Mary Pat Knadler
P304
P356
10.2174/157488608784529189
P577
2008-05-01T00:00:00Z